What Is Off-Label Prescribing? A Patient's Guide

What Does Off-Label Prescribing Mean?

Off-label prescribing happens when your doctor prescribes an FDA-approved medication for a use, patient group, or dose not listed on the official label. The medicine itself has passed strict FDA safety testing for human use. However, the specific way you are using it has not gone through the formal FDA approval process for that exact condition.

This practice occurs because medical science often moves much faster than the regulatory labeling process. Doctors observe how medications work in the real world, and peer-reviewed research accumulates to support new uses. Over time, clinical guidelines evolve to recommend these treatments long before a manufacturer updates the official label.

Off-label prescribing is a routine, legally protected aspect of medical practice governed by your clinician's professional judgment.

• FDA-approved label: This covers the specific indications, dosages, patient populations, and administration routes submitted by the manufacturer, but it does not dictate all medically valid uses.
• Unapproved drug vs. unapproved use: An unapproved drug has never been cleared by the FDA for human use, whereas an unapproved use involves a fully vetted, FDA-approved medication.
• FDA acknowledgment: The FDA explicitly recognizes that off-label prescribing is a valid practice, noting that good medical care often requires using approved drugs for unapproved indications.²

Why Do Doctors Prescribe Medications Off-Label?

Clinicians frequently prescribe an off-label treatment when current medical evidence supports a use that the FDA label has not yet caught up to. Sometimes, your unique symptoms do not fit neatly into the specific conditions studied during the original clinical trials. In these cases, doctors rely on their training and peer-reviewed research to find the best solution for you.

The FDA approval process is incredibly expensive and driven by pharmaceutical companies. Manufacturers may choose not to spend hundreds of millions of dollars to add a new indication to a label, especially for older, generic medications. Off-label prescribing fills a critical gap between regulatory timelines and clinical reality.

• No approved treatment exists: For certain rare conditions or specific patient populations, there is no FDA-approved medication available, making an off-label option the only pharmacological choice.
• Clinical evidence supports a new use: Peer-reviewed studies, case series, and formal clinical guidelines often recommend a drug for an indication that is not on the original label.
• Patient has not responded to labeled treatments: A clinician may determine that an off-label medication is medically appropriate based on your history of treatment-resistant symptoms.
• Pediatric and special populations: Many drugs are only approved for adults because manufacturers rarely conduct pediatric trials, making pediatric off-label use extremely common.
• Cost and regulatory barriers: Pursuing a new FDA indication is a massive financial investment, so companies often skip this step even when strong evidence supports a new application.

How Common Is Off-Label Prescribing?

Off-label prescribing is deeply embedded in the standard of care across nearly every medical specialty. Research indicates that approximately 21% of all outpatient prescriptions in the U.S. are written for off-label uses.¹ This means that roughly one in five prescriptions you receive might be off-label.

Certain fields of medicine rely on off-label studies and prescribing more heavily than others. In oncology, tumor biology evolves much faster than regulatory labels, while in pediatrics, clinical trial data is often scarce. Psychiatry also frequently utilizes off-label prescribing, as many first-line medications effectively treat conditions beyond their narrow original approvals.

Common Off-Label Use Examples

Many off-label uses are so well-established that patients and even some healthcare providers do not realize the application is technically off-label. These medications have robust clinical research supporting their alternative uses. In many cases, professional medical organizations officially recommend them in their clinical guidelines.

The label simply has not been updated by the manufacturer to reflect current medical practice.

• GLP-1 receptor agonists: Some formulations (such as Ozempic) are FDA-approved for type 2 diabetes only, and prescribed off-label for weight management. While others (such as Wegovy and Zepbound) are explicitly FDA-approved for weight management.
• Gabapentin: FDA-approved for epilepsy and postherpetic neuralgia; commonly prescribed off-label for fibromyalgia, generalized neuropathic pain, and anxiety disorders.
• Trazodone: FDA-approved for major depressive disorder; one of the most frequently prescribed sleep aids in the U.S., almost entirely off-label.
• Propranolol: FDA-approved for hypertension, certain cardiac conditions, and migraine prophylaxis; widely used off-label for performance anxiety and essential tremor.
• Metformin: FDA-approved for type 2 diabetes; used off-label for polycystic ovary syndrome (PCOS) and weight management.
• Ketamine: FDA-approved as an anesthetic since 1970 and on the WHO List of Essential Medicines since 1985; prescribed off-label for depression, anxiety, PTSD, and chronic pain, supported by a substantial body of peer-reviewed psychiatric research.³

Is Off-Label Prescribing Legal?

Yes, off-label prescribing is entirely legal throughout the United States. The FDA regulates drug manufacturing, labeling, and marketing, but it does not regulate the practice of medicine. Once a medication is FDA-approved for any reason, a licensed clinician may prescribe it for any use they determine is medically appropriate.

The FDA regulates drug approval, manufacturing, labeling, and marketing, while state medical boards and professional standards govern how clinicians prescribe approved medications in practice. The actual practice of medicine is governed by state medical boards and professional liability standards.

Pharmaceutical manufacturers are generally prohibited from marketing drugs for unapproved uses, though certain scientific and regulatory communications may be permitted under specific rules. This distinction between prescribing (which is legal) and promoting (which is restricted) is a cornerstone of American healthcare law.

• The FDA regulates drugs, not doctors: The agency explicitly states that healthcare providers may prescribe approved medications for unapproved uses.²
• Manufacturer promotion is restricted: Under the Federal Food, Drug, and Cosmetic Act, pharmaceutical companies cannot market a drug for an indication that it does not possess.
• State medical boards govern care: Professional liability standards and state boards determine whether a specific off-label prescription meets the accepted standard of care.

Are There Risks Associated With Off-Label Prescribing?

When a drug is used off-label, the specific application has not undergone the FDA's formal review process for that exact indication. This means the manufacturer-submitted efficacy and safety data on the label may not directly apply to your condition.

However, this does not mean there is no evidence supporting the treatment. It simply means the evidence exists in peer-reviewed literature, clinical guidelines, and real-world data rather than on the official FDA label. The primary risk involves the variability of this external evidence.

Some off-label uses have decades of randomized controlled trials supporting them, while others rely on smaller studies or preliminary data. The Agency for Healthcare Research and Quality (AHRQ) has noted that off-label uses supported by weak evidence carry higher rates of adverse events.⁵

The risk is not inherent to the off-label status itself, but rather depends on the quality of the evidence and the level of clinical oversight. Well-supported off-label uses prescribed within defined clinical protocols carry a fundamentally different risk profile than poorly evidenced ones prescribed without monitoring.

• Variable evidence quality: Some off-label uses have robust clinical trial support, while others are based on preliminary data or case series.
• Insurance coverage gaps: Payers may not cover off-label uses unless they are supported by recognized medical compendia.
• Informed consent: Patients should always understand when a prescription is off-label, what evidence supports it, and what side effects to monitor.

How Does Insurance Cover Off-Label Prescriptions?

Insurance coverage for off-label prescriptions is not automatic, but it is far more common than most patients realize. Coverage often depends on whether the specific off-label use is listed in authoritative, evidence-based drug references known as compendia.

These compendia, such as the AHFS Drug Information or the NCCN Drugs & Biologics Compendium, evaluate off-label uses independently of manufacturer labeling. Medicare is actually required by law to cover off-label uses supported by recognized compendia, and many private insurers follow similar frameworks.

Patients should ask their clinician and insurer about coverage before assuming an off-label prescription will be denied out of pocket.

• Medicare coverage: Mandated for compendium-supported off-label uses under the Social Security Act.⁶
• Private insurers: Coverage varies, but many major providers frequently follow compendium-based frameworks.
• Prior authorization: Appeals or prior authorizations may be required, and clinicians can provide supporting medical literature to assist.
• Alternative payment options: Some at-home ketamine therapy programs accept HSA and FSA payments and provide Superbills for potential insurance reimbursement.

Ketamine as an Off-Label Treatment in Psychiatry

Ketamine is one of the most well-researched examples of off-label prescribing in modern medicine. It has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.³ Today, licensed clinicians prescribe it off-label for psychiatric conditions, including depression, anxiety, and PTSD.

This off-label treatment is supported by a substantial and well-established body of peer-reviewed research spanning over two decades. Studies published in journals like JAMA Psychiatry and the American Journal of Psychiatry report clinically meaningful benefits for some patients with depression and related psychiatric conditions.⁷

Ketamine temporarily modulates neural communication by interacting with the NMDA receptor, which increases neuroplasticity and strengthens neural connections. Because of this mechanism, many people report noticeable symptom improvement within hours or days of their first session.

Off-label ketamine prescribing follows the exact same legal and clinical framework as every other off-label use discussed in this guide. For example, Mindbloom applies this same framework through clinician evaluation, structured treatment protocols, and follow-up support in its at-home ketamine program.

What Is the Difference Between Ketamine and Spravato (Esketamine)?

Spravato (esketamine) is the S-enantiomer of ketamine, manufactured by Janssen, and received FDA approval in 2019 specifically for treatment-resistant depression. It requires administration in a certified healthcare setting with a mandatory two-hour observation period and is available only as a nasal spray.⁸

Ketamine is a racemic compound—meaning it contains both the S and R enantiomers—available as a generic medication. It has been used medically since 1970 and is administered via multiple routes (intravenous, sublingual, subcutaneous, intramuscular) as an off-label treatment for psychiatric conditions.

The FDA approval of Spravato reflects both a manufacturer's decision to pursue a specific regulatory pathway and the FDA's review of evidence for a particular formulation, route of administration, and indication; it does not mean off-label ketamine lacks supporting research. Different administration routes, settings, and cost structures suit different clinical needs.

How Structured Clinical Protocols Support Safe Off-Label Prescribing

A defined clinical protocol is the combination of screening, clinician oversight, monitoring, and follow-up that determines whether any prescription is delivered safely. Comprehensive medical and psychiatric screening helps identify contraindications before treatment begins.

Clinician-determined dosing based on individual assessment, ongoing monitoring, and clear escalation pathways for adverse events are essential components. This is where the safety of off-label treatment lives—not in the label itself, but in the clinical framework surrounding the prescription.

Mindbloom provides a specific, evidence-backed implementation of this framework for at-home ketamine therapy. The program includes clinician consults, a required peer treatment monitor present during every session, guide coaching for preparation and integration, and unlimited Group Integration Circles.

Building on decades of clinical research on ketamine's therapeutic applications, Mindbloom has published two of the largest peer-reviewed outcomes studies of at-home ketamine therapy.⁴ ⁹ These studies were conducted on Mindbloom clients using the Mindbloom protocol.

In a peer-reviewed study of 11,441 patients, 89% of clients reported improvement in their depression symptoms, and 56.4% met criteria for response.⁴ These outcomes reflect the safety and clinical protocols that underpin every Mindbloom treatment.

However, Mindbloom's reported depression response rates exceed those reported in selected SSRI antidepressant studies¹⁰ and selected meta-analyses of talk therapy.¹¹ Response rates are comparable to or modestly exceed those reported in selected IV ketamine studies.¹² Mindbloom is also the only at-home ketamine provider offering subcutaneous administration in addition to sublingual tablets.

Disclaimer

IMPORTANT SAFETY INFORMATION
‍Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary.Full safety information: www.mindbloom.com/safety-information‍

‍OFF-LABEL USE DISCLOSURE
‍Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.